The prognostic value of serum C-reactive protein-bound serum amyloid A in early-stage lung cancer  

作　　者：Xue-Yan Zhang Ge Zhang Ying Jiang Dan Liu Man-Zhi Li Qian Zhong Shan-Qi Zeng Wan-Li Liu Mu-Sheng Zeng 

机构地区：[1]State Key Laboratory of Oncology in South China,Collaborative Innovation Center for Cancer Medicine,Sun Yat-sen University Cancer Center [2]Department of Experimental Research,Sun Yat-sen University Cancer Center [3]Department of Pathogenic Biology,Guangzhou Hoffmann Institute of Immunology,School of Basic Sciences,Guangzhou Medical University [4]Department of Microbial and Biochemical Pharmacy,School of Pharmaceutical Sciences,Sun Yat-sen University [5]State Key Laboratory of Proteomics,Beijing Proteome Research Center,Beijing Institute of Radiation Medicine [6]Department of Clinical Laboratory,Sun Yat-sen University Cancer Center [7]Department of Gastrointestinal Surgery,Guangzhou Digestive Disease Center,Guangzhou First People's Hospital,Guangzhou Medical University

出　　处：《Chinese Journal of Cancer》2015年第8期335-349,共15页

基　　金：supported by grants from the Ministry of Science and Technology of China(2011CB504304 and 2012CB967003);the National Natural Science Foundation of China(81271902 and 81230045)

摘　　要：Background:Elevated levels of serum C-reactive protein(CRP) have been reported to have prognostic significance in lung cancer patients.This study aimed to further identify CRP-bound components as prognostic markers for lung cancer and validate their prognostic value.Methods:CRP-bound components obtained from the serum samples from lung cancer patients or healthy controls were analyzed by differential proteomics analysis.CRP-bound serum amyloid A(CRP-SAA) was evaluated by coimmunoprecipitation(IP).Serum samples from two independent cohorts with lung cancer(retrospective cohort,242patients;prospective cohort,222 patients) and healthy controls(159 subjects) were used to evaluate the prognostic value of CRP-SAA by enzyme-linked immunosorbent assay.Results:CRP-SAA was identified specifically in serum samples from lung cancer patients by proteomic analysis.CRP binding to SAA was confirmed by co-IP in serum samples from lung cancer patients and cell culture media.The level of CRP-SAA was significantly higher in patients than in healthy controls(0.37 ± 0.58 vs.0.03 ± 0.04,P < 0.001).Elevated CRP-SAA levels were significantly associated with severe clinical features of lung cancer.The elevation of CRPSAA was associated with lower survival rates for both the retrospective(hazard ration[HR]= 2.181,95%confidence interval[CI]= 1.641-2.897,P < 0.001) and the prospective cohorts(HR = 2.744,95%CI = 1.810-4.161,P < 0.001).Multivariate Cox analysis showed that CRP-SAA was an independent prognostic marker for lung cancer.Remarkably,in stages l-ll patients,only CRP-SAA,not total SAA or CRP,showed significant association with overall survival in two cohorts.Moreover,univariate and multivariate Cox analyses also showed that only CRP-SAA could be used as an independent prognostic marker for early-stage lung cancer patients.Conclusion:CRP-SAA could be a better prognostic marker for lung cancer than total SAA or CRP,especially in earlystage patients.Background： Elevated levels of serum C-reactive protein （CRP） have been reported to have prognostic significance in lung cancer patients.This study aimed to further identify CRP-bound components as prognostic markers for lung cancer and validate their prognostic value. Methods： CRP-bound components obtained from the serum samples from lung cancer patients or healthy controls were analyzed by differential proteomics analysis. CRP-bound serum amyloid A （CRP-SAA） was evaluated by coimmunoprecipitation （IP）. Serum samples from two independent cohorts with lung cancer （retrospective cohort, 242 patients; prospective cohort, 222 patients） and healthy controls （159 subjects） were used to evaluate the prognostic value of CRP-SAA by enzyme-linked immunosorbent assay. Results： CRP-SAA was identified specifically in serom samples from lung cancer patients by proteomic analysis. CRP binding to SAA was confirmed by co-IP in serum samples from lung cancer patients and cell culture media.The level of CRP-SAA was significantly higher in patients than in healthy controls （0.37 4- 0.58 vs. 0.03 4- 0.04, P 〈 0.001）. Elevated CRP-SAA levels were significantly associated with severe clinical features of lung cancer.The elevation of CRP- SAA was associated with lower survival rates for both the retrospective （hazard ration [HR] = 2.181, 95% confidence interval [CI] = 1.641-2.897, P 〈 0.001） and the prospective cohorts （HR - 2.744, 95% CI = 1.810-4.161, P 〈 0.001 ）. Multivariate Cox analysis showed that CRP-SAA was an independent prognostic marker for lung cancer. Remarkably, in stages Ⅰ-Ⅱ patients, only CRP-SAA, not total SAA or CRP, showed significant association with overall survival in two cohorts. Moreover, univariate and multivariate Cox analyses also showed that only CRP-SAA could be used as an independent prognostic marker for early-stage lung cancer patients. Conclusion： CRP-SAA could be a better prognostic marker for lung cancer than total SAA or CRP, especially in earlystage

关 键 词：C反应蛋白 血清样品 肺癌 预后 价值 早期 结合物 酶联免疫吸附试验 

分 类 号：R734.2[医药卫生—肿瘤]